CN1326348A - 利鲁唑和α-生育酚缔合物 - Google Patents
利鲁唑和α-生育酚缔合物 Download PDFInfo
- Publication number
- CN1326348A CN1326348A CN99813190A CN99813190A CN1326348A CN 1326348 A CN1326348 A CN 1326348A CN 99813190 A CN99813190 A CN 99813190A CN 99813190 A CN99813190 A CN 99813190A CN 1326348 A CN1326348 A CN 1326348A
- Authority
- CN
- China
- Prior art keywords
- riluzole
- alpha
- associated complex
- tocopherol
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fats And Perfumes (AREA)
- External Artificial Organs (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Saccharide Compounds (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Cosmetics (AREA)
Abstract
α-生育酚和利鲁唑或该化合物在药学上可接受的盐的缔合物以及这种缔合物在治疗肌萎缩性侧索硬化方面的用途。
Description
本发明涉及利鲁唑(RILUZOLE)或在药学上可接受的这种化合物的盐和α-生育酚的缔合物以及这种缔合物在治疗肌萎缩性侧索硬化(SLA)方面的用途。
CHARCOT在1865年第一次描述也被称作CHARCOT病和LOU GEHRIG病的肌萎缩性侧索硬化。SLA是一种由运动神经元退化造成的致死疾病。这种疾病伴随逐渐麻痹,因此导致丧失运动和呼吸功能,而后在出现第一个症兆后2-8年内死亡。
直到今天,仅存在以RILUTEK商品名销售的利鲁唑(2-氨基-6-三氟甲氧基苯并噻唑)用于治疗肌萎缩性侧索硬化。利鲁唑原则上能够延缓疾病的发展。
现在发现,利鲁唑或其药学上可接受的盐与α-生育酚(α-生育酚)的缔合物比仅用利鲁唑能够更显著地延缓这种疾病发展,还能够缓解患者的疲劳和降低血浆中丙二醛的浓度。
对总数为289位年龄在18岁以上的患者进行研究,这些患者患有SLA不到5年,其肿活量/理论肺活量之比高于或等于60%(肺活量是通常的呼吸功能的常规度量,也称作呼吸功能试验)。
这些患者分成两组:
第一组:145位患者通过口服100毫克/天利鲁唑和口服1000毫克/天α-生育酚进行治疗,
第二组:144位患者通过口服100毫克/天利鲁唑和安慰剂进行治疗。
这2组患者中在第二次评价中不再符合给药标准或未正确地进行合理治疗的某些患者未被考虑进行结果确定。
这些患者被跟踪一年。这些结果根据功能等级(Munsat功能阶段(RIVIERE等人,Arch.Neurol.,55,526(1998)),类比的易疲劳性目视等级(EVA)(LACOMBLEZ及其同事,Lancet,347,1425(1996);Bensimon及其同事,新英格兰医学杂志(New England Journal of Medicine),330,585(1994))和血浆中丙二醛浓度,氧化性应激的生物化学标记物(FAVIER,生物系统中自由基分析(Analysis of free radical inbiological system),Birk Hauser,Basel/Switzerland,1995,第100-117页)度量。
Munsat功能阶段A涉及一般或中等阶段的患者:
-一般阶段:在3个方面(语言、手臂和下肢)一般地出现功能缺陷,在语言能力、日常生活和步行中上肢活动方面出现功能自主性,
-中等阶段:在3个方面一般地出现功能缺陷,或在一个方面中等至严重地出现功能缺陷,而另外两个方面是正常的或稍微产生不利影响。
Munsat功能阶段B涉及严重级或最后阶段患者:
-严重阶段:需要在2或3个方面得到帮助,构音障碍和/或行走需要帮助和/或日常生活中上肢活动需要帮助的患者,
-最后阶段:至少2个方面非功能使用和第3方面中等使用或非功能使用。
在给药时刻(M0)和治疗12个月后(M12)测定了功能阶段A和B的变化。得到如下结果:
利鲁唑和安慰剂(患者数) | 利鲁唑和α-生育酚(患者数) | |
给药时刻(M0)A级B级 | 10910 | 11210 |
治疗后状态(M12)A级B级 | 5663 | 7349 |
这些结果表明,在用利鲁唑和安慰剂治疗12个月之后,53位患者(44.5%)病情恶化,66位患者(55.3%)没有变化,而在经过利鲁唑和α-生育酚缔合物治疗的患者中只有39位患者(32%)病情恶化,83位患者(68%)没有变化。
因此,给药利鲁唑和α-生育酚缔合物比只用利鲁唑可以进一步减缓病情发展。
根据类比的目视等级(EVA),测定给药时刻(M0)和3个月(M3)后的易疲劳性。
在这个试验中,得到如下平均值:
M0时刻的EVA(毫米) | M3时刻的EVA(毫米) | M0与M3之差(毫米) | |
利鲁唑和安慰剂(115位患者) | 48.4 | 65.7 | 17.3 |
利鲁唑和α-生育酚缔合物(118位患者) | 46.4 | 58.6 | 12.2 |
这些值清楚地表明,通过利鲁唑和α-生育酚缔合物治疗的患者与通过利鲁唑和安慰剂治疗的患者相比,疲劳程度更低。
在给药时刻(M0)和3个月(M3)时测定作为SLA变化预示性因素的血浆中丙二醛浓度。
得到的浓度平均值如下:
M0时刻的浓度(微摩尔) | M3时刻的浓度(微摩尔) | M3与M0之差(微摩尔) | |
利鲁唑和安慰剂(65位患者) | 2.94±0.40 | 2.72±0.40 | 0.22±0.40 |
利鲁唑和α-生育酚(58位患者) | 2.86±0.40 | 2.36±0.30 | 0.50±0.50 |
这些结果表明,患有肌萎缩性侧索硬化的患者体内血浆丙二醛浓度(M0时刻浓度)增加,治疗期间降低,但使用利鲁唑和α-生育酚缔合物与只使用利鲁唑和安慰剂的情况相比,降低程度更明显。
作为药学上可接受的利鲁唑盐,特别可以列举与无机酸的加合盐,例如盐酸盐、硫酸盐、硝酸盐、磷酸盐,或与有机酸的加合盐,例如乙酸盐、丙酸盐、琥珀酸盐、草酸盐、苯甲酸盐、富马酸盐、马来酸盐、甲磺酸盐、羟乙磺酸盐、茶叶碱-乙酸盐、水杨酸盐、酚酞酸盐、亚甲基-双-β-萘酚酸盐或这些衍生物的取代衍生物。
该缔合物可以通过口服、肠胃道外或直肠同时、分别地或在时间上错开地分期用药。
本发明还涉及含有纯的或为与一种或多种相容的和药学上可接受的稀释剂和/或添加剂组合的形式和/或任选地与另外一种药学上相容的和生理学活性化合物结合的利鲁唑和α-生育酚缔合物的药物组合物。
作为口服的固体组合物,可以使用片、丸、粉剂(胶囊、凝胶、片)或颗粒剂。在这些组合物中,在氩气流下,让这些活性组分与一种或多种惰性稀释剂如淀粉、纤维素、蔗糖、乳糖或二氧化硅混合。这些组合物还可以含有除稀释剂之外的物质,例如一种或多种润滑剂如硬脂酸镁或滑石、着色剂、包裹剂(糖衣)或漆。
作为口服液体组合物,可以使用含有惰性稀释剂如水、乙醇、甘油、植物油或石蜡油的药学上可接受的溶液、悬混液、乳液、糖浆和酏剂。这些组合物可以含有除稀释剂之外的物质,例如润湿剂、甜味剂、增稠剂、芳香剂或稳定剂。
灭菌的肠胃道外用药组合物优选地可以是含水或非水溶液、悬混液或乳液。作为溶剂或载体,可以使用水、丙二醇、聚乙二醇、植物油,特别是橄榄油、可注射有机酯,例如油酸乙酯或其它合适的有机溶剂。这些组合物还可以含有助剂,特别是润湿剂、等渗剂、乳化剂、分散剂和稳定剂。灭菌可以多种方式如采用通过在组合物中加入灭菌剂进行灭菌过滤、辐照或加热的方式进行。它们还可以制成灭菌固体组合物,在使用时将这些组合物溶于无菌水或任何其它可注射无菌介质中。
直肠给药组合物是除了活性产品以外还含有载体如椰子油、半合成甘油酯或聚乙二醇的栓剂或直肠用胶囊。
本发明还涉及对患有肌萎缩性侧索硬化的患者进行治疗的方法,其中包括同时、分别地或在时间上错开地分期向患者给药利鲁唑或它在药学上可接受的盐和α-生育酚的缔合物。
使用的剂量取决于要求达到的效果、治疗时间和给药方式;其剂量一般是成人每天口服10-400毫克、单位剂量为10-200毫克的利鲁唑,成人每天口服250-4000毫克、单位剂量为100-1000毫克的α-生育酚。
一般地,医生将依据待治疗者的年龄、体重和其它固有因素确定合适的剂量。
Claims (6)
1、α-生育酚和利鲁唑或该化合物在药学上可接受的盐的缔合物。
2、根据权利要求1的缔合物,其中每250-4000重量份α-生育酚使用10-400重量份利鲁唑。
3、根据权利要求1或2的缔合物,其中它可被用作同时、分别地或在时间上错开地分期使用的合并制剂。
4、根据权利要求1-3中任一项的缔合物,其中它可被用于治疗肌萎缩性侧索硬化。
5、利鲁唑在制备权利要求1的缔合物方面的用途。
6、由纯的权利要求1的缔合物或在任何相容的和药学上可接受的稀释剂或添加剂存在下所述缔合物组成的组合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9814250A FR2785808B1 (fr) | 1998-11-13 | 1998-11-13 | Association riluzole et alpha-tocopherol |
FR98/14250 | 1998-11-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1326348A true CN1326348A (zh) | 2001-12-12 |
CN1177587C CN1177587C (zh) | 2004-12-01 |
Family
ID=9532674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998131903A Expired - Fee Related CN1177587C (zh) | 1998-11-13 | 1999-11-09 | 利鲁唑和α-生育酚联合制剂 |
Country Status (23)
Country | Link |
---|---|
US (2) | US6642262B2 (zh) |
EP (1) | EP1128829B1 (zh) |
JP (1) | JP4693241B2 (zh) |
KR (1) | KR100641472B1 (zh) |
CN (1) | CN1177587C (zh) |
AT (1) | ATE295168T1 (zh) |
AU (1) | AU776242B2 (zh) |
BR (1) | BR9915292A (zh) |
CA (1) | CA2350671C (zh) |
CZ (1) | CZ298808B6 (zh) |
DE (1) | DE69925301T2 (zh) |
DK (1) | DK1128829T3 (zh) |
EA (1) | EA003671B1 (zh) |
ES (1) | ES2239858T3 (zh) |
FR (1) | FR2785808B1 (zh) |
HK (1) | HK1041220B (zh) |
HU (1) | HU226067B1 (zh) |
IL (1) | IL142708A0 (zh) |
NO (1) | NO328349B1 (zh) |
PT (1) | PT1128829E (zh) |
TR (1) | TR200101346T2 (zh) |
WO (1) | WO2000028992A1 (zh) |
ZA (1) | ZA200103810B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2786101B1 (fr) * | 1998-11-24 | 2002-07-05 | Aventis Laboratoire | Utilisation de la nicergoline dans le traitement de la spasticite |
AU2006305309A1 (en) * | 2005-10-18 | 2007-04-26 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis |
US20070099156A1 (en) * | 2005-10-28 | 2007-05-03 | Jeff Wagner | Self-etching dental primer compositions and methods and systems utilizing such compositions |
FR2957077B1 (fr) * | 2010-03-02 | 2012-04-13 | Univ Dauvergne Clermont I | Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux |
WO2014145776A2 (en) * | 2013-03-15 | 2014-09-18 | Baylor College Of Medicine | Msp and its receptors in the therapy of amyotrophic lateral sclerosis |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2688138B1 (fr) * | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique. |
US5843641A (en) * | 1993-02-26 | 1998-12-01 | Massachusetts Institute Of Technology | Methods for the daignosis, of familial amyotrophic lateral sclerosis |
US6380252B1 (en) * | 1996-07-05 | 2002-04-30 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1 |
US5780489A (en) * | 1996-08-21 | 1998-07-14 | Brooks; Benjamin Rix | Method for treating amyotrophic lateral sclerosis |
JP3889844B2 (ja) * | 1997-02-10 | 2007-03-07 | 龍兒 梶 | 筋萎縮性側索硬化症治療剤 |
FR2782008B1 (fr) * | 1998-08-07 | 2003-04-25 | Sod Conseils Rech Applic | Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique |
-
1998
- 1998-11-13 FR FR9814250A patent/FR2785808B1/fr not_active Expired - Fee Related
-
1999
- 1999-11-09 TR TR2001/01346T patent/TR200101346T2/xx unknown
- 1999-11-09 CA CA2350671A patent/CA2350671C/fr not_active Expired - Fee Related
- 1999-11-09 BR BR9915292-4A patent/BR9915292A/pt not_active Application Discontinuation
- 1999-11-09 AU AU11655/00A patent/AU776242B2/en not_active Ceased
- 1999-11-09 EA EA200100530A patent/EA003671B1/ru not_active IP Right Cessation
- 1999-11-09 IL IL14270899A patent/IL142708A0/xx not_active IP Right Cessation
- 1999-11-09 CN CNB998131903A patent/CN1177587C/zh not_active Expired - Fee Related
- 1999-11-09 PT PT99972101T patent/PT1128829E/pt unknown
- 1999-11-09 DK DK99972101T patent/DK1128829T3/da active
- 1999-11-09 WO PCT/FR1999/002753 patent/WO2000028992A1/fr active IP Right Grant
- 1999-11-09 ES ES99972101T patent/ES2239858T3/es not_active Expired - Lifetime
- 1999-11-09 EP EP99972101A patent/EP1128829B1/fr not_active Expired - Lifetime
- 1999-11-09 AT AT99972101T patent/ATE295168T1/de active
- 1999-11-09 JP JP2000582039A patent/JP4693241B2/ja not_active Expired - Fee Related
- 1999-11-09 CZ CZ20011561A patent/CZ298808B6/cs not_active IP Right Cessation
- 1999-11-09 HU HU0105301A patent/HU226067B1/hu not_active IP Right Cessation
- 1999-11-09 DE DE69925301T patent/DE69925301T2/de not_active Expired - Lifetime
- 1999-11-09 KR KR1020017005912A patent/KR100641472B1/ko not_active IP Right Cessation
-
2001
- 2001-05-10 ZA ZA200103810A patent/ZA200103810B/en unknown
- 2001-05-10 NO NO20012308A patent/NO328349B1/no not_active IP Right Cessation
- 2001-05-11 US US09/854,318 patent/US6642262B2/en not_active Expired - Lifetime
-
2002
- 2002-04-22 HK HK02102998.6A patent/HK1041220B/zh not_active IP Right Cessation
-
2003
- 2003-02-18 US US10/369,151 patent/US20030125363A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69904079T2 (de) | Kombinationen von ileumgallensäuretransports inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen | |
CA2168247C (en) | Nitric oxide donor composition and method for treatment of anal disorders | |
CA1238280A (en) | Pharmaceutical compositions containing bilobalid | |
AU2010290795B2 (en) | Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same | |
KR20000069594A (ko) | 관절염의 신규 치료 방법 | |
RU2207866C2 (ru) | ПРИМЕНЕНИЕ ФОСФОЛИПИДНЫХ КОМПЛЕКСОВ ЭКСТРАКТОВ ИЗ vitis vinifera В КАЧЕСТВЕ ПРОТИВОАТЕРОСКЛЕРОТИЧЕСКИХ АГЕНТОВ | |
WO1989000848A1 (en) | Method for the treatment of body tissues and the administration of drugs thereto | |
CN1177587C (zh) | 利鲁唑和α-生育酚联合制剂 | |
PT1562577E (pt) | Acetil-l-carnitina para a prevenção e/ou tratamento de neuropatias periféricas induzidas pela talidomida | |
EP3701956B1 (en) | Prophylactic and/or therapeutic agent for dementia | |
EP0215956A1 (en) | Composition for treating skin disease | |
WO1998046226A1 (en) | Method for treating schizophrenia | |
NZ530367A (en) | Use of ginkgo biloba extracts for preparing a medicine for treating sarcopenia | |
EP1944030A1 (en) | Agent for treatment of schizophrenia | |
EP0279867A2 (de) | Verwendung von Vitamin-E und Vitamin-E-Kombination mit nichtsteroidalen Antirheumatika und Schmerzmittel zur Behandlung von rheumatischen Erkrankungen | |
CN1899329A (zh) | 具有降血脂功效的药物组合物 | |
DE3232031A1 (de) | Pharmazeutisches mittel zum hemmen des wucherns glatter muskelzellen | |
CN1440287A (zh) | 治疗外周血管疾病、外周神经病和自主神经病的方法 | |
KR100662903B1 (ko) | 글루코사민 하이드로클로라이드를 함유하는 당뇨 질환치료용 의약 조성물 | |
WO2006065792A2 (en) | Treatment of interstitial cystitis using cannabinoid analogs | |
CN1055634C (zh) | 降低血粘度的贴剂 | |
EP0934040A1 (en) | Method for treating dementia due to aids | |
KR20030004333A (ko) | 과민성 대장증후군 (ibs)의 치료에 대한로플레포나이드의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20041201 Termination date: 20171109 |
|
CF01 | Termination of patent right due to non-payment of annual fee |